|
1
|
Early Breast Cancer Trialists'
Collaborative Group (EBCTCG), . Effects of chemotherapy and
hormonal therapy for early breast cancer on recurrence and 15-year
survival: An overview of the randomised trials. Lancet.
365:1687–1717. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Gianni L, Pienkowski T, Im YH, Tseng LM,
Liu MC, Lluch A, Starosławska E, de la Haba-Rodriguez J, Im SA,
Pedrini JL, et al: 5-year analysis of neoadjuvant pertuzumab and
trastuzumab in patients with locally advanced, inflammatory, or
early-stage HER2-positive breast cancer (NeoSphere): A multicentre,
open-label, phase 2 randomised trial. Lancet Oncol. 17:791–800.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Baum M: Modern concepts of the natural
history of breast cancer: A guide to the design and publication of
trials of the treatment of breast cancer. Eur J Cancer. 49:60–64.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Clarke R, Leonessa F and Trock B:
Multidrug resistance/P-glycoprotein and breast cancer: Review and
meta-analysis. Semin Oncol. 32 Suppl 7:S9–S15. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Ferlay J, Soerjomataram I, Dikshit R, Eser
S, Mathers C, Rebelo M, Parkin DM, Forman D and Bray F: Cancer
incidence and mortality worldwide: Sources, methods and major
patterns in GLOBOCAN 2012. Int J Cancer. 136:E359–E386. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Heximer SP, Lim H, Bernard JL and Blumer
KJ: Mechanisms governing subcellular localization and function of
human RGS2. J Biol Chem. 276:14195–14203. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Bosch DE, Zielinski T, Lowery RG and
Siderovski DP: Evaluating modulators of ‘regulator of G-protein
signaling’ (RGS) proteins. Curr Protoc Pharmacol: Chapter. 2:Unit
2.82012.
|
|
8
|
Nguyen CH, Ming H, Zhao P, Hugendubler L,
Gros R, Kimball SR and Chidiac P: Translational control by RGS2. J
Cell Biol. 186:755–765. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Cao X, Qin J, Xie Y, Khan O, Dowd F,
Scofield M, Lin MF and Tu Y: Regulator of G-protein signaling 2
(RGS2) inhibits androgen-independent activation of androgen
receptor in prostate cancer cells. Oncogene. 25:3719–3734. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Hurst JH, Mendpara N and Hooks SB:
Regulator of G-protein signalling expression and function in
ovarian cancer cell lines. Cell Mol Biol Lett. 14:153–174. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Zhu Y, Hollmen J, Räty R, Aalto Y, Nagy B,
Elonen E, Kere J, Mannila H, Franssila K and Knuutila S:
Investigatory and analytical approaches to differential gene
expression profiling in mantle cell lymphoma. Br J Haematol.
119:905–915. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Schwable J, Choudhary C, Thiede C,
Tickenbrock L, Sargin B, Steur C, Rehage M, Rudat A, Brandts C,
Berdel WE, et al: RGS2 is an important target gene of Flt3-ITD
mutations in AML and functions in myeloid differentiation and
leukemic transformation. Blood. 105:2107–2114. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Kannangai R, Vivekanandan P,
Martinez-Murillo F, Choti M and Torbenson M: Fibrolamellar
carcinomas show overexpression of genes in the RAS, MAPK, PIK3 and
xenobiotic degradation pathways. Hum Pathol. 38:639–644. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Smalley MJ, Iravani M, Leao M, Grigoriadis
A, Kendrick H, Dexter T, Fenwick K, Regan JL, Britt K, McDonald S,
et al: Regulator of G-protein signalling 2 mRNA is differentially
expressed in mammary epithelial subpopulations and over-expressed
in the majority of breast cancers. Breast Cancer Res. 9:R852007.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Lyu JH, Park DW, Huang B, Kang SH, Lee SJ,
Lee C, Bae YS, Lee JG and Baek SH: RGS2 suppresses breast cancer
cell growth via a MCPIP1-dependent pathway. J Cell Biochem.
116:260–267. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Ellis IO, Collins L, Ichihara S, et al:
Invasive carcinoma of no special typeLakhani SR, Ellis IO, Schnitt
SJ, Tan PH and van de Vijver MJ: WHO classification of tumours of
the breast. Fourth. IARC 34; Lyon: 2012
|
|
17
|
Subramanian A, Tamayo P, Mootha VK,
Mukherjee S, Ebert BL, Gillette MA, Paulovich A, Pomeroy SL, Golub
TR, Lander ES and Mesirov JP: Gene set enrichment analysis: A
knowledge-based approach for interpreting genome-wide expression
profiles. Proc Natl Acad Sci USA. 102:pp. 15545–15550. 2005;
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Colditz G and Chia KS: Invasive breast
carcinoma: Introduction and general featuresWHO classification of
tumours of the breast. Fourth. IARC 23; Lyon: 2012
|
|
19
|
Spoerke JM, Gendreau S, Walter K, Qiu J,
Wilson TR, Savage H, Aimi J, Derynck MK, Chen M, Chan IT, et al:
Heterogeneity and clinical significance of ESR1 mutations in
ER-positive metastatic breast cancer patients receiving
fulvestrant. Nat Commun. 7:115792016. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Parker JS, Mullins M, Cheang MC, Leung S,
Voduc D, Vickery T, Davies S, Fauron C, He X, Hu Z, et al:
Supervised risk predictor of breast cancer based on intrinsic
subtypes. J Clin Oncol. 27:1160–1167. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Clarke RB: Steroid receptors and
proliferation in the human breast. Steroids. 68:789–794. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Schiff R, Osborne CK and Fuqua SAW:
Clinical aspects of estrogen and prog-esterone receptors. Wolters
Kluwer Lippincott Williams & Wilkins; Philadelphia: 2010
|
|
23
|
Rakha EA, El-Sayed ME, Lee AH, Elston CW,
Grainge MJ, Hodi Z, Blamey RW and Ellis IO: Prognostic significance
of Nottingham histologic grade in invasive breast carcinoma. J Clin
Oncol. 26:3153–3158. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Rakha EA, Reis-Filho JS, Baehner F, Dabbs
DJ, Decker T, Eusebi V, Fox SB, Ichihara S, Jacquemier J, Lakhani
SR, et al: Breast cancer prognostic classification in the molecular
era: The role of histological grade. Breast Cancer Res. 12:2072010.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Cleton-Jansen AM: E-cadherin and loss of
heterozygosity at chromosome 16 in breast carcinogenesis: Different
genetic pathways in ductal and lobular breast cancer? Breast Cancer
Res. 4:5–8. 2002. View
Article : Google Scholar : PubMed/NCBI
|
|
26
|
Lacroix-Triki M, Suarez PH, MacKay A,
Lambros MB, Natrajan R, Savage K, Geyer FC, Weigelt B, Ashworth A
and Reis-Filho JS: Mucinous carcinoma of the breast is genomically
distinct from invasive ductal carcinomas of no special type. J
Pathol. 222:282–298. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Marchiò C, Iravani M, Natrajan R, Lambros
MB, Geyer FC, Savage K, Parry S, Tamber N, Fenwick K, Mackay A, et
al: Mixed micropapillary-ductal carcinomas of the breast: A genomic
and immunohistochemical analysis of morphologically distinct
components. J Pathol. 218:301–315. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Persson M, Andrén Y, Mark J, Horlings HM,
Persson F and Stenman G: Recurrent fusion of MYB and NFIB
transcription factor genes in carcinomas of the breast and head and
neck. Proc Natl Acad Sci USA. 106:pp. 18740–18744. 2009; View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Tognon C, Knezevich SR, Huntsman D,
Roskelley CD, Melnyk N, Mathers JA, Becker L, Carneiro F,
MacPherson N, Horsman D, et al: Expression of the ETV6-NTRK3 gene
fusion as a primary event in human secretory breast carcinoma.
Cancer cell. 2:367–376. 2002. View Article : Google Scholar : PubMed/NCBI
|
